Maven Securities’s Gossamer Bio GOSS Stock Holding History

Maven Securities’s Portfolio GOSS Stock Details GOSS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-624	Closed	-$433K	–	974
2022 Q1	$433K	Buy	+624	New	+$481K	0.02%	582

Other funds holding GOSS

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Maven Securities's GOSS Position: Q2 2022 in Review

Maven Securities sold out of Gossamer Bio (GOSS) in Q2 2022, closing a stake of 624 shares — an estimated $433K sold.

Maven Securities first reported a position in GOSS in Q1 2022 and held it in 1 quarter. The position peaked at $433K in Q1 2022. 127 funds tracked by Wall St. Rank hold GOSS as of Q2 2022.

Maven Securities reported no remaining Gossamer Bio position as of Q2 2022 after selling out during the quarter.
Maven Securities sold 624 Gossamer Bio shares in Q2 2022, an estimated $433K.
Maven Securities first reported a position in Gossamer Bio in Q1 2022 and held it in 1 quarter.
Maven Securities's Gossamer Bio position peaked at $433K in Q1 2022.
127 funds tracked by Wall St. Rank held Gossamer Bio as of Q2 2022.

Based on Maven Securities's 13F filing for Q2 2022, filed 15 Aug 2022.